Aubri M Waters1, Hyun J Park1, Andrew L Weskamp2, Allyson Mateja3, Megan E Kachur4, Jonathan J Lyons5, Benjamin J Rosen6, Nathan A Boggs7. 1. Allergy and Immunology Service, Walter Reed National Military Medical Center, Bethesda, Md. 2. Internal Medicine Service, Walter Reed National Military Medical Center, Bethesda, Md. 3. Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Md. 4. Department of Pathology, Walter Reed National Military Medical Center, Bethesda, Md. 5. Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 6. Hematopathology Service, Walter Reed National Military Medical Center, Bethesda, Md. 7. Allergy and Immunology Service, Walter Reed National Military Medical Center, Bethesda, Md; Department of Medicine, Uniformed Services University, Bethesda, Md. Electronic address: nathan.a.boggs3.mil@mail.mil.
Abstract
BACKGROUND: Hereditary-alpha tryptasemia (HαT) is the most common etiology for elevated basal serum tryptase (BST). However, the utility of tryptase genotyping of individuals with elevated BST in general clinical practice remains undefined. Moreover, studies showing associations between elevated BST and chronic kidney disease (CKD), myelodysplastic syndrome (MDS), rheumatoid arthritis, or eosinophilic esophagitis did not include tryptase genotyping. OBJECTIVE: To determine the utility of tryptase genotyping among individuals with moderate elevations in BST at a regional health system. METHODS: Clinical and laboratory data from 109 subjects with basal tryptase values of 7.5 ng/mL or greater who were tested for HαT or had a disorder previously linked to elevated BST were collected retrospectively by chart review. RESULTS: Fifty-eight subjects had elevated BST defined as 11.5 ng/mL or greater. HαT was found in 63.8% (n = 37), 12.1% (n = 7) had CKD, and 20.7% (n = 12) had clonal myeloid disorders. A total of 6.9% (n = 4) with elevated BST had negative testing for HαT, CKD, and myeloid neoplasms. Two subjects with CKD, 1 subject with MDS, and 1 with myeloid hypereosinophilic syndrome had negative testing for HαT. Among subjects with elevated BST and more than 1 tryptase measurement, 41.5% (n = 22) had BST variability that exceeded the 20% plus 2 formula. Increased BST variability was found in subjects with HαT, all forms of mastocytosis, CKD, MDS, and those with no associated diagnosis. CONCLUSIONS: HαT, CKD, and clonal myeloid disorders or a combination of the 3 constitute approximately 90% of individuals with elevated BST in clinical practice. Myeloid neoplasms were over-represented in this cohort relative to population prevalence data suggesting tryptase measurement selection bias by clinicians or higher prevalence. Elevated BST is associated with increased tryptase variability, regardless of etiology. Published by Elsevier Inc.
BACKGROUND: Hereditary-alpha tryptasemia (HαT) is the most common etiology for elevated basal serum tryptase (BST). However, the utility of tryptase genotyping of individuals with elevated BST in general clinical practice remains undefined. Moreover, studies showing associations between elevated BST and chronic kidney disease (CKD), myelodysplastic syndrome (MDS), rheumatoid arthritis, or eosinophilic esophagitis did not include tryptase genotyping. OBJECTIVE: To determine the utility of tryptase genotyping among individuals with moderate elevations in BST at a regional health system. METHODS: Clinical and laboratory data from 109 subjects with basal tryptase values of 7.5 ng/mL or greater who were tested for HαT or had a disorder previously linked to elevated BST were collected retrospectively by chart review. RESULTS: Fifty-eight subjects had elevated BST defined as 11.5 ng/mL or greater. HαT was found in 63.8% (n = 37), 12.1% (n = 7) had CKD, and 20.7% (n = 12) had clonal myeloid disorders. A total of 6.9% (n = 4) with elevated BST had negative testing for HαT, CKD, and myeloid neoplasms. Two subjects with CKD, 1 subject with MDS, and 1 with myeloid hypereosinophilic syndrome had negative testing for HαT. Among subjects with elevated BST and more than 1 tryptase measurement, 41.5% (n = 22) had BST variability that exceeded the 20% plus 2 formula. Increased BST variability was found in subjects with HαT, all forms of mastocytosis, CKD, MDS, and those with no associated diagnosis. CONCLUSIONS: HαT, CKD, and clonal myeloid disorders or a combination of the 3 constitute approximately 90% of individuals with elevated BST in clinical practice. Myeloid neoplasms were over-represented in this cohort relative to population prevalence data suggesting tryptase measurement selection bias by clinicians or higher prevalence. Elevated BST is associated with increased tryptase variability, regardless of etiology. Published by Elsevier Inc.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker Journal: Arthritis Rheum Date: 2010-09
Authors: Bjorn van Anrooij; Joanne N G Oude Elberink; Lambert F R Span; Jan G R de Monchy; Stefano Rosati; André B Mulder; Johanna C Kluin-Nelemans Journal: J Allergy Clin Immunol Date: 2018-06-08 Impact factor: 10.793
Authors: Catherine R Weiler; K Frank Austen; Cem Akin; Marla S Barkoff; Jonathan A Bernstein; Patrizia Bonadonna; Joseph H Butterfield; Melody Carter; Charity C Fox; Anne Maitland; Thanai Pongdee; S Shahzad Mustafa; Anupama Ravi; Mary C Tobin; Harissios Vliagoftis; Lawrence B Schwartz Journal: J Allergy Clin Immunol Date: 2019-08-30 Impact factor: 10.793
Authors: W R Sperr; J H Jordan; M Baghestanian; H P Kiener; P Samorapoompichit; H Semper; A Hauswirth; G H Schernthaner; A Chott; S Natter; D Kraft; R Valenta; L B Schwartz; K Geissler; K Lechner; P Valent Journal: Blood Date: 2001-10-01 Impact factor: 22.113
Authors: Peter Valent; Amy D Klion; Hans-Peter Horny; Florence Roufosse; Jason Gotlib; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Joseph H Butterfield; Wolfgang R Sperr; Karl Sotlar; Peter Vandenberghe; Torsten Haferlach; Hans-Uwe Simon; Andreas Reiter; Gerald J Gleich Journal: J Allergy Clin Immunol Date: 2012-03-28 Impact factor: 10.793
Authors: Allyson Mateja; Qinlu Wang; Jack Chovanec; Jiwon Kim; Kenneth J Wilson; Lawrence B Schwartz; Sarah C Glover; Melody C Carter; Dean D Metcalfe; Erica Brittain; Jonathan J Lyons Journal: J Allergy Clin Immunol Date: 2021-08-20 Impact factor: 14.290
Authors: Georg Greiner; Bettina Sprinzl; Aleksandra Górska; Franz Ratzinger; Michael Gurbisz; Nadine Witzeneder; Klaus G Schmetterer; Bettina Gisslinger; Goekhan Uyanik; Emir Hadzijusufovic; Harald Esterbauer; Karoline V Gleixner; Maria T Krauth; Michael Pfeilstöcker; Felix Keil; Heinz Gisslinger; Boguslaw Nedoszytko; Marek Niedoszytko; Wolfgang R Sperr; Peter Valent; Gregor Hoermann Journal: Blood Date: 2021-01-14 Impact factor: 22.113